Hemab Therapeutics

HemaB

Hemab Therapeutics develops prophylactic antibody therapies for patients with rare bleeding and thrombotic disorders including Glanzmann thrombasthenia and Factor VII deficiency.

Tectonic Therapeutic

This biotechnology firm develops protein and antibody therapies targeting G-protein coupled receptors to treat patients with pulmonary hypertension and genetic bleeding disorders.

Prophylix Pharma AS

The company develops antibody-based prophylactic treatments for fetal and neonatal alloimmune thrombocytopenia to prevent life-threatening bleeding and brain injury in newborns.

RougeTx

This biotechnology company develops small-molecule therapies that restore vascular stability to treat patients with hereditary haemorrhagic telangiectasia and other bleeding disorders.

Imara

This biopharmaceutical company develops oral small-molecule therapies to treat patients with rare genetic blood disorders, including sickle cell disease and beta thalassemia.

Prophylix Pharma

This company develops antibody therapies to treat fetal and neonatal alloimmune thrombocytopenia in unborn babies and newborns.

Human Immunology Biosciences (HI-Bio)

This biotechnology company develops targeted immunotherapies for patients with rare, severe immune-mediated diseases, such as chronic kidney conditions and antibody-mediated transplant rejection.

True North Therapeutics

This biotechnology company develops monoclonal antibodies targeting the complement system to treat patients with rare blood, kidney and skin diseases.